Aderans Research to Enroll 200th Subject in Hair Loss Clinical Trial

The company is on target to enroll its 200th subject in its Phase 2 hair loss clinical study by the end of this year

Nov 2010

Aderans Research Institute (ARI) is approaching a key milestone in its hair regeneration program. The company is on target to enroll its 200th subject in its Phase 2 clinical study by the end of this year. This expansion reflects the advances in ARI’s cell engineering solutions for those with pattern hair loss.

“The results are very encouraging and are reinforcing the scientific basis of our technology and product offering,” said Kurt Stenn, M.D., Vice President Research and Chief Scientific Officer.

Ken Washenik, M.D. Ph.D., Executive Vice President commented, “This clinical study is starting to show how our innovative cell-based approach to hair restoration can truly help those who suffer from hair loss.”

Launched in November 2008, Phase 2 is focused on finding the most promising cell product treatment from ARI’s Ji Gami™ family of unique products. The 200th subject will be a major landmark in the trial for ARI, as the company will be two-thirds of the way to its goal of almost 300 subjects. Phase 2 completion is expected by the beginning of 2012.

Phase 2 is being conducted across the United States for individuals suffering from androgenetic alopecia. Vern Liebmann, Vice President, Operations added, “It is ARI’s hope that our state-of-the-art cell engineering solutions will continue to both positively impact those in the study and eventually set the standard for the industry as a whole.”

“We are very pleased and excited by the progress of ARI. They are critical to the future of Unihair and pioneering the field of hair regeneration,” said Tadao Otsuki, President and CEO of Unihair, parent company of ARI and a leading hair loss solutions company.

For more information about the Phase 2 clinical trial, visit http://www.aderansresearch.com/ari_clinicupdates.html.

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research is a subsidiary of Unihair Co., Ltd, the world’s largest wig manufacturer, and affiliate of Bosley, a global leader in surgical hair restoration.

Ongoing information on ARI’s clinical study can be seen at http://aderansresearch.com/ari_clinicalupdates.html

Source